In the face of a growing epidemic of opioid abuse, new strategies must be developed to help combat this dire situation. With approximately 1.8 million individuals currently dependent on opioids in the USA, this webinar explored the underlying issues associated with opioid abuse and addiction, reviewing the role of abuse deterrent formulations (ADFs) in combating the problem. Learn more about strategies for preventing opioid abuse, common methods of abuse and the factors that must be taken into account for successful in vivo studies of ADFs.
What will you learn?
- Why we need ADFs
- The various manipulations and the relationship between in vitro and in vivo studies
- The nuances of working with abuse deterrent products
Who will this interest?
- Project Managers
- Clinical Consultants
- Formulation Development Specialists
- CMC Professionals
- QA & RA Managers
Scott Smiley, RPh, has been the Director of Pharmacy Operations on over 170 clinical research studies for Vince & Associates Clinical Research, an Altasciences company. Scott is a graduate of The University of Kansas School of Pharmacy and has over 20 years of clinical practice and research expertise as a licensed pharmacist. He is highly skilled with both sterile intravenous preparations and extemporaneous compounding. Scott works with all types of early phase clinical studies, and specializes in complex trials such as those involving abuse deterrent preparation and manipulation. Scott is also certified by APhA in Pharmacy-Based Immunization Delivery, and has trained at the Professional Compounding Centers of America.